ArticleDermatology and therapy2024

Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial.

Ian M Catlett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.